KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Keros Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$11.06+0.40 (+3.75%)
Close on Oct 19, 2026
- Market cap
- $218.99M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Operating margin
27.7%
Net margin
35.7%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -37.4% | 19.9% | |
| Return on assets | – | -32.4% | 18.2% | |
| Current ratio | – | 37.27 | 15.45 | |
| Interest coverage | – | -7776.2× | – | |
| Capex to revenue | – | – | 0.6% | |
| Diluted shares | – | 16M | 38M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Keros Therapeutics generated $525.09M from operations and spent $383.21M on capital expenditure, dividends and share buybacks. 2% of that went back into the business.
Generated
$525.09M
Used
$383.21M
Capital expenditure$8.21M2%Dividends$00%Share buybacks$375.00M98%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin35.7%
×Asset turnover0.51×
×Equity multiplier1.09×
=Return on equity, FY202519.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 35.7% | 0.51× | 1.09× | 19.9% |
| FY2023 | -101319.2% | 0.00× | 1.11× | -50.2% |
| FY2021 | -292.3% | 0.08× | 1.04× | -23.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$87.01M
- Cash generatingOperating cash flow above zero$107.51M
- Return on assets improvedROA up on the prior year-50.6% → 14.1%
- Earnings backed by cashOperating cash flow above net income$107.51M vs $87.01M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose21.45 → 15.45
- No dilutionShare count did not rise37M → 38M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.40